Author Archives: Joana Carvalho

Tegsedi Approved for Reimbursement in Portugal

The Portuguese Medicine Regulatory Authority, known as Infarmed, has added Tegsedi (inotersen) — an approved treatment for stage 1 or 2 polyneuropathy in adults with familial amyloid polyneuropathy (FAP) — to the list of reimbursed medications for patients living in Portugal. Tegsedi now will be the…

Tegsedi Available to FAP Patients in Spain at Reduced Cost

Spain’s Ministry of Health has added Tegsedi (inotersen), an injection  treatment for stage 1 or 2 polyneuropathy in adults with familial amyloid polyneuropathy (FAP), to the national list of prescription medicines that patients are reimbursed for using. With this decision, Tegsedi will be the first at-home…

FDA Places Vutrisiran on Fast Track as Potential FAP Treatment for Adults

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alnylam Pharmaceuticals’ vutrisiran as a potential treatment of adults with familial amyloid polyneuropathy (FAP). Fast track is intended to accelerate the development and review of investigational therapies aimed at treating serious or life-threatening conditions, and…

Sudoscan Test of Sweat Gland Function May Improve FAP Diagnosis, Study Says

Sudoscan, a device that evaluates sweat gland function, may help physicians improve the diagnosis of familial amyloid polyneuropathy — distinguishing these patients from those with chronic inflammatory demyelinating polyneuropathy, a study says. The study, “Quantitative sudomotor test helps differentiate Transthyretin familial amyloid polyneuropathy from Chronic…